PRCT vs. NVO

Last updated Apr 1, 2026

Compare and contrast key facts about PROCEPT BioRobotics Corporation (PRCT) and Novo Nordisk A/S (NVO).

Performance

PRCT vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in PROCEPT BioRobotics Corporation (PRCT) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

PRCT vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
PRCT PROCEPT BioRobotics Corporation	-20.50%	-60.93%	92.13%	0.89%	66.09%	-40.37%
NVO Novo Nordisk A/S	-25.12%	-39.22%	-15.93%	54.84%	22.66%	10.60%

Fundamentals

EPS PRCT : -$2.58 NVO : $22.15
PS Ratio PRCT : 3.01 NVO : 0.55
Total Revenue (TTM) PRCT : $308.05M NVO : $297.20B
Gross Profit (TTM) PRCT : $196.23M NVO : $240.66B
EBITDA (TTM) PRCT : -$89.40M NVO : $153.18B

Returns By Period

In the year-to-date period, PRCT achieves a -20.50% return, which is significantly higher than NVO's -25.12% return.

PRCT

• 1D: -2.11%
• 1M: 10.22%
• YTD: -20.50%
• 6M: -29.92%
• 1Y: -57.07%
• 3Y*: -4.15%
• 5Y*: —
• 10Y*: —

NVO

• 1D: 4.14%
• 1M: 1.73%
• YTD: -25.12%
• 6M: -31.34%
• 1Y: -44.52%
• 3Y*: -20.64%
• 5Y*: 3.88%
• 10Y*: 5.13%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

PRCT vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRCT

PRCT Risk / Return Rank: 7
PRCT Sharpe Ratio Rank: 5
PRCT Sortino Ratio Rank: 5
PRCT Omega Ratio Rank: 7
PRCT Calmar Ratio Rank: 8
PRCT Martin Ratio Rank: 12

NVO

NVO Risk / Return Rank: 12
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 11
NVO Calmar Ratio Rank: 14
NVO Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PRCT vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for PROCEPT BioRobotics Corporation (PRCT) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	PRCT	NVO	Difference
Sharpe ratio Return per unit of total volatility	-0.97	-0.82	-0.15
Sortino ratio Return per unit of downside risk	-1.61	-1.02	-0.59
Omega ratio Gain probability vs. loss probability	0.82	0.86	-0.04
Calmar ratio Return relative to maximum drawdown	-0.90	-0.79	-0.11
Martin ratio Return relative to average drawdown	-1.42	-1.37	-0.05
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

PRCT vs. NVO - Sharpe Ratio Comparison

The current PRCT Sharpe Ratio is -0.97, which is comparable to the NVO Sharpe Ratio of -0.82. The chart below compares the historical Sharpe Ratios of PRCT and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	PRCT	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.97	-0.82	-0.15
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	0.10	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.16	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.17	0.46	-0.63

Correlation

The correlation between PRCT and NVO is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

PRCT vs. NVO - Dividend Comparison

PRCT has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 5.06%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
PRCT PROCEPT BioRobotics Corporation	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	5.06%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

PRCT vs. NVO - Drawdown Comparison

The maximum PRCT drawdown since its inception was -77.18%, roughly equal to the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for PRCT and NVO.

Drawdown Indicators

	PRCT	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-77.18%	-74.70%	-2.48%
Max Drawdown (1Y) Largest decline over 1 year	-65.12%	-55.03%	-10.09%
Max Drawdown (5Y) Largest decline over 5 years	—	-74.70%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-74.70%	—
Current Drawdown Current decline from peak	-74.85%	-73.25%	-1.60%
Average Drawdown Average peak-to-trough decline	-30.01%	-17.55%	-12.46%
Ulcer Index Depth and duration of drawdowns from previous peaks	40.98%	31.69%	+9.29%

Volatility

PRCT vs. NVO - Volatility Comparison

PROCEPT BioRobotics Corporation (PRCT) has a higher volatility of 21.09% compared to Novo Nordisk A/S (NVO) at 9.88%. This indicates that PRCT's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PRCT	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	21.09%	9.88%	+11.21%
Volatility (6M) Calculated over the trailing 6-month period	44.70%	38.79%	+5.91%
Volatility (1Y) Calculated over the trailing 1-year period	58.84%	54.20%	+4.64%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.84%	37.82%	+27.02%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.84%	32.29%	+32.55%

Financials

PRCT vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between PROCEPT BioRobotics Corporation and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

PRCT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, PROCEPT BioRobotics Corporation reported a gross profit of 46.31M and revenue of 76.38M. Therefore, the gross margin over that period was 60.6%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.

PRCT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, PROCEPT BioRobotics Corporation reported an operating income of -31.04M and revenue of 76.38M, resulting in an operating margin of -40.6%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.

PRCT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, PROCEPT BioRobotics Corporation reported a net income of -29.85M and revenue of 76.38M, resulting in a net margin of -39.1%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.